Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medtech Venture Investing 2010: Do the Right Thing

This article was originally published in Start Up

Executive Summary

In March 2010, Elsevier Business Intelligence convened a panel of venture capitalists and CEOs of devicestart-ups to discuss the climate for early and late stage funding. Their conclusion: there is money out there, if companies do the right things.

You may also be interested in...

Medtech Risk Capital? Anything But. A VC Roundtable from IN3

A year and a half after the September 2008 collapse of Lehman Brothers and the official start of the economic recession, a panel of venture capitalists and other financiers in the medical device industry came together at the IN3 meeting in Boston. We asked them if they've had to change the way they look at deals. What is the trade-off between expensive, de-risked later stage deals and the kinds of returns that can be achieved by backing a winning company from start to finish? Where would they place their bets: cost-effective technologies for tried-and-true markets or novel products for unmet clinical needs, the "evolutionary vs. revolutionary" debate? And what can one do about tired syndicates? Our panel lets us in on the kinds of discussions they've been having around the table at weekly partners' meetings.

Insulin Device Companies' New Mantra: Real Simple

Companies developing devices for diabetes have to ask a question that companies in other medical device fields don't: what about the users, the people with diabetes? How will they use the device? Because in diabetes care, management of the disease is left up to the patient, who is asked to self-test blood glucose levels, self-administer insulin by injection, and pay attention to diet and exercise. Acknowledging that the patient is the single most important contributor to success in diabetes care, start-up companies have set out to make insulin delivery easier. With a focus on ease of use as a clinical advantage, start-ups are offering new insulin delivery devices for two distinct markets: the full-featured (but easy to use) insulin pump for Type 1 diabetes, and the disposable, simple insulin patch/infuser for Type 2.

Device Prom Song: Looks Like We Made It

A year ago, things looked bleak everywhere, including devices. But investors and executives battened down the hatches, tightened their belts, and adopted every other conceivable austerity-tied cliché. Things now are beginning to look up…a little.

Related Content

Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts